Short Term Results of Topical Cyclosporin A in Patients with vernal Keratoconjunctivitis

Aykut Arslan Yıldız
Yavuz Bardak


Objective: The aim of this study to investigate short term effects of topical cyclosporin A 0.05% in patients with vernal keratoconjunctivitis.

Materials and Methods: Seventeen patients diagnosed vernal keratoconjuntivitis were classified with allergic conjunctivitis classification (absent, mild, moderate, severe) to evaluate symptoms and 5-5-5 exarbation grading scale for allergic conjuntivitis disease (mild, moderate, severe) to evaluate findings. Topical cyclosporin A (0.05%) was applied to all patients and they were evaluated in 1st, 3rd and 6th months. Chi-square test was used for statistical analysis.

Results: Mean age was 14 ± 3.5 (male\female: 12\5). There were 11 (64.7%) severe hyperemia, 1 (5.9%) severe mucous discharge, 11 (64.7%) severe itching and 1 (5.9%) severe tearing before the treatment. Severe symptoms weren’t observed in any cases after the treatment in 6th month. Hyperemia in 1 (5.9%) case, mucous discharge in 12 (70.5%) cases, itching in 12 (70.5%) cases, tearing in 7 (41.1%) cases were treated completely in 6th month. Alterations in hyperemia (p< 0.001), mucous discharge (p< 0.001), itching (p< 0.001), tearing (p< 0.001) were significant in statistical evaluation. Mild 9 (53%) cases, moderate 7 (41.1%) cases, severe 1 (5.9%) case were classified according to 5-5-5 exarbation grading scale for allergic conjuntivitis disease before the treatment. Mild 11 (64.7%) cases, moderate 5 (29.4%) cases, severe 1 (5.9%) case were established in 6th month. Alterations in the findings weren’t established significantly in statistical evaluation.

Conclusion: To apply topical cyclosporin A %0.05 in patients with vernal keratoconjuntivitis may cause to symptomatic regression significantly in short term.


Vernal keratoconjunctivitis, cyclosporin A
Tüm hakları saklıdır. © 2016 AAI